Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE L'IDENTIFICATION D'UN BIOMARQUEUR PLASMATIQUE MARQUEUR DE L'ACTIVITÉ DU MASITINIB DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE, ET CAPABLE...
-
PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING...
-
Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late...
-
CervoMed's neflamapimod has been selected for the U.K.’s EXPERTS-ALS platform to rapidly evaluate it in ALS
-
New York, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Łukasz Sznajder, PhD, MSc, Assistant Professor, Department of Chemistry and Biochemistry,...
-
Presentation highlights Phase 1 trial completion, FDA Fast Track and Orphan Drug designations, and the expanding pipeline-in-a-product potential of TRE-515
-
PathMaker Neurosystems Board Director, John Donoghue, Ph.D., Awarded 2026 Queen Elizabeth Prize for Engineering
-
PathMaker Neurosystems Announces Completion of ALS Early Feasibility Study of the MyoRegulator Device for Non-Invasive Treatment of ALS
-
Athira Pharma, Inc. today announced that it has changed its name to LeonaBio, Inc.
-
First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates in ALS, FTD and traumatic brain injury.